Abstract | BACKGROUND: METHODS: The Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols ( PRISMA-P) guidelines was used to design this meta-analysis protocol. The final study will also be conducted under the PRISMA guidelines for systematic reviews and meta-analyses. The core bibliographic database search will be carried out by 2 reviewers working individually, with each conducting an initial screening based on titles and abstracts. The shortlisted articles will be selected for review and statistical analysis based on predefined inclusion and exclusion criteria. Study characteristics, relevant clinicopathological characteristics and statistical data required for meta-analysis (hazard ratios [HRs] and 95% confidence interval [CIs) will be extracted and compiled into a MS Excel datasheet. Meta-analysis will be performed, using a random-effects model, and the results (pooled HR and 95% CI) will be presented in the form of a forest plot. Publication bias will also be assessed by use of Egger bias indicator test and funnel plot symmetry. If data are insufficient, a narrative line of review will be pursued. DISCUSSION: HE4 protein has been shown to have great potential for clinical use as a diagnostic and prognostic marker in epithelial ovarian cancer (EOC). However, HE4 is not only limited to expression in ovarian cancer, but is also overexpressed in lung and endometrial cancers. The effectiveness of HE4 as a biomarker in cancers (other than EOC) has not yet been studied in the form of a comprehensive systematic review and meta-analysis. The results of this study should allow for expanded use of HE4 as a multiutility biomarker in multiple cancer types, thereby, elevating HE4's value as a cancer biomarker. PROSPERO REGISTRATION: CRD42019120326.
|
Authors | Chellan Kumarasamy, Madurantakam Royam Madhav, Shanthi Sabarimurugan, Kartik Lakhotiya, Venkatesh Pandey, T Priyadharshini, Siddhratha Baxi, K M Gothandam, Rama Jayaraj |
Journal | Medicine
(Medicine (Baltimore))
Vol. 98
Issue 28
Pg. e15336
(Jul 2019)
ISSN: 1536-5964 [Electronic] United States |
PMID | 31305389
(Publication Type: Journal Article)
|
Chemical References |
- Biomarkers, Tumor
- Proteins
- WAP Four-Disulfide Core Domain Protein 2
- WFDC2 protein, human
|
Topics |
- Biomarkers, Tumor
(metabolism)
- Carcinoma
(diagnosis, metabolism)
- Humans
- Meta-Analysis as Topic
- Prognosis
- Proteins
(metabolism)
- Research Design
- Systematic Reviews as Topic
- WAP Four-Disulfide Core Domain Protein 2
|